Comment on “Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease”: treatment comparison or treatment sequencing?
本文未提供摘要，请点击“查看全文”查看完整内容。